Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis
Objectives: There are many explanations for increased levels of serum uric acid (SUA) in patients with psoriatic arthritis (PsA), but correlation with different treatment options in PsA is not well elucidated. Our aim was to determine the effects of biological disease-modifying antirheumatic drugs (...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/47/3/142 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850205610548658176 |
|---|---|
| author | Dijana Perković Marin Petrić Maja Maleš Ivana Erceg Maleš Mislav Radić |
| author_facet | Dijana Perković Marin Petrić Maja Maleš Ivana Erceg Maleš Mislav Radić |
| author_sort | Dijana Perković |
| collection | DOAJ |
| description | Objectives: There are many explanations for increased levels of serum uric acid (SUA) in patients with psoriatic arthritis (PsA), but correlation with different treatment options in PsA is not well elucidated. Our aim was to determine the effects of biological disease-modifying antirheumatic drugs (bDMARDs) on SUA levels in patients with PsA. Materials and methods: We analyzed the data of PsA patients treated with different bDMARDs from January 2007 to June 2021. Patients treated with interleukin-17 (IL-17) inhibitors (secukinumab and ixekizumab) and tumor necrosis factor α (TNFα) inhibitors (golimumab, infliximab, adalimumab, certolizumab pegol, and etanercept) were included. Results: A total of 87 patients were included. The SUA levels decreased in 60 (69%) patients after a 3–6-month-long follow-up, and in 25 (28.7%), we noticed an increase. The average decrease in SUA levels was 9.4 ± 49.5 µmol/L (<i>p</i> = 0.039); for TNFα patients, it was 7.3 ± 59.8 µmol/L (<i>p</i> = 0.386), and for IL-17 patients, it was 12.6 ± 28.4 µmol/L (<i>p</i> = 0.013). The levels of SUA decreased in 81.8% of patients treated with infliximab, as well as in 76% of those treated with secukinumab and in 72.7% of those treated with etanercept. The largest average decrease in SUA levels was recorded in the group treated with golimumab (23 µmol/L). Conclusions: A significant decrease in SUA levels was noticed, especially in patients treated with IL-17 inhibitors. Further studies should identify which bDMARD is the most potent in the lowering of SUA levels. bDMARDs were efficient in PsA disease activity. |
| format | Article |
| id | doaj-art-02f205bed19e4ec89a035f0ba4a02c18 |
| institution | OA Journals |
| issn | 1467-3037 1467-3045 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj-art-02f205bed19e4ec89a035f0ba4a02c182025-08-20T02:11:04ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452025-02-0147314210.3390/cimb47030142Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic ArthritisDijana Perković0Marin Petrić1Maja Maleš2Ivana Erceg Maleš3Mislav Radić4Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, CroatiaDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, CroatiaDepartment of Internal Medicine, School of Medicine, University of Split, 21000 Split, CroatiaDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, CroatiaDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, CroatiaObjectives: There are many explanations for increased levels of serum uric acid (SUA) in patients with psoriatic arthritis (PsA), but correlation with different treatment options in PsA is not well elucidated. Our aim was to determine the effects of biological disease-modifying antirheumatic drugs (bDMARDs) on SUA levels in patients with PsA. Materials and methods: We analyzed the data of PsA patients treated with different bDMARDs from January 2007 to June 2021. Patients treated with interleukin-17 (IL-17) inhibitors (secukinumab and ixekizumab) and tumor necrosis factor α (TNFα) inhibitors (golimumab, infliximab, adalimumab, certolizumab pegol, and etanercept) were included. Results: A total of 87 patients were included. The SUA levels decreased in 60 (69%) patients after a 3–6-month-long follow-up, and in 25 (28.7%), we noticed an increase. The average decrease in SUA levels was 9.4 ± 49.5 µmol/L (<i>p</i> = 0.039); for TNFα patients, it was 7.3 ± 59.8 µmol/L (<i>p</i> = 0.386), and for IL-17 patients, it was 12.6 ± 28.4 µmol/L (<i>p</i> = 0.013). The levels of SUA decreased in 81.8% of patients treated with infliximab, as well as in 76% of those treated with secukinumab and in 72.7% of those treated with etanercept. The largest average decrease in SUA levels was recorded in the group treated with golimumab (23 µmol/L). Conclusions: A significant decrease in SUA levels was noticed, especially in patients treated with IL-17 inhibitors. Further studies should identify which bDMARD is the most potent in the lowering of SUA levels. bDMARDs were efficient in PsA disease activity.https://www.mdpi.com/1467-3045/47/3/142biological disease-modifying antirheumatic drugsinterleukin-17psoriatic arthritistumor necrosis factor alphauric acid |
| spellingShingle | Dijana Perković Marin Petrić Maja Maleš Ivana Erceg Maleš Mislav Radić Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis Current Issues in Molecular Biology biological disease-modifying antirheumatic drugs interleukin-17 psoriatic arthritis tumor necrosis factor alpha uric acid |
| title | Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis |
| title_full | Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis |
| title_fullStr | Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis |
| title_full_unstemmed | Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis |
| title_short | Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis |
| title_sort | biological disease modifying antirheumatic drugs decrease uric acid levels in the sera of patients with psoriatic arthritis |
| topic | biological disease-modifying antirheumatic drugs interleukin-17 psoriatic arthritis tumor necrosis factor alpha uric acid |
| url | https://www.mdpi.com/1467-3045/47/3/142 |
| work_keys_str_mv | AT dijanaperkovic biologicaldiseasemodifyingantirheumaticdrugsdecreaseuricacidlevelsintheseraofpatientswithpsoriaticarthritis AT marinpetric biologicaldiseasemodifyingantirheumaticdrugsdecreaseuricacidlevelsintheseraofpatientswithpsoriaticarthritis AT majamales biologicaldiseasemodifyingantirheumaticdrugsdecreaseuricacidlevelsintheseraofpatientswithpsoriaticarthritis AT ivanaercegmales biologicaldiseasemodifyingantirheumaticdrugsdecreaseuricacidlevelsintheseraofpatientswithpsoriaticarthritis AT mislavradic biologicaldiseasemodifyingantirheumaticdrugsdecreaseuricacidlevelsintheseraofpatientswithpsoriaticarthritis |